Your browser is no longer supported. Please, upgrade your browser.
Settings
MBVX MabVax Therapeutics Holdings, Inc. daily Stock Chart
MBVX [NASD]
MabVax Therapeutics Holdings, Inc.
Index- P/E- EPS (ttm)-3.99 Insider Own1.00% Shs Outstand16.72M Perf Week-4.30%
Market Cap11.20M Forward P/E- EPS next Y-2.38 Insider Trans0.00% Shs Float12.61M Perf Month44.06%
Income-26.10M PEG- EPS next Q-0.70 Inst Own1.80% Short Float6.85% Perf Quarter-56.43%
Sales0.00M P/S- EPS this Y73.00% Inst Trans8.67% Short Ratio2.11 Perf Half Y-70.49%
Book/sh0.01 P/B66.99 EPS next Y18.20% ROA-229.40% Target Price18.00 Perf Year-85.93%
Cash/sh0.11 P/C6.22 EPS next 5Y- ROE- 52W Range0.43 - 4.85 Perf YTD-80.18%
Dividend- P/FCF- EPS past 5Y60.90% ROI-216.40% 52W High-86.19% Beta1.27
Dividend %- Quick Ratio0.30 Sales past 5Y- Gross Margin- 52W Low56.89% ATR0.11
Employees22 Current Ratio0.30 Sales Q/Q- Oper. Margin- RSI (14)50.79 Volatility25.62% 18.19%
OptionableNo Debt/Eq- EPS Q/Q-59.70% Profit Margin- Rel Volume4.71 Prev Close0.74
ShortableYes LT Debt/Eq- EarningsAug 24 Payout- Avg Volume408.70K Price0.67
Recom2.00 SMA2016.94% SMA50-0.79% SMA200-66.44% Volume1,927,013 Change-9.47%
Sep-22-17 03:30PM  MabVax Therapeutics Holdings, Inc. Announces $1.25 Million Registered Direct Offering PR Newswire -9.47%
Sep-20-17 01:21PM  Why You Need To Look At This Factor Before Buying MabVax Therapeutics Holdings Inc (MBVX) Simply Wall St. +19.74%
Sep-13-17 08:05AM  MabVax Therapeutics' HuMab-5B1 Antibody to be Featured in Presentations at the 2017 World Molecular Imaging Congress PR Newswire +22.03%
Sep-12-17 08:05AM  MabVax Therapeutics Holdings, Inc. Announces $2.0 Million Registered Direct Offering PR Newswire -10.61%
Sep-07-17 08:05AM  MabVax Therapeutics Holdings, Inc. to Present at the 19th Annual Rodman & Renshaw Global Investment Conference in New York City PR Newswire +6.67%
Sep-06-17 08:05AM  MabVax Therapeutics Engages Greenhill & Co. as Advisor for Exploring Strategic Alternatives PR Newswire
Aug-22-17 04:05PM  MabVax Therapeutics Holdings, Inc. Announces the Closing of $1.3 Million Registered Direct Offering and is Engaging an Advisory Bank to Explore Strategic Alternatives PR Newswire
Aug-14-17 08:10AM  MabVax Therapeutics Holdings, Inc. Announces Pricing of Registered Direct Offering PR Newswire
Jul-24-17 08:00AM  MabVax Therapeutics Board of Directors Authorizes the Company to Explore Strategic Alternatives PR Newswire +19.64%
Jun-27-17 08:05AM  MabVax Therapeutics Commences Patient Dosing in MVT-1075 Radioimmunotherapy Phase 1 Clinical Trial for the Treatment of Pancreatic, Colon and Lung Cancers PR Newswire
Jun-14-17 07:05AM  MabVax Therapeutics Reports Positive Phase 1 Results for MVT-2163 ImmunoPET Imaging Agent PR Newswire +9.09%
Jun-07-17 07:05AM  MabVax Therapeutics ImmunoPET Imaging Agent MVT-2163 to be Featured in Two Presentations at the 2017 SNMMI Annual Meeting PR Newswire
Jun-05-17 07:00AM  MabVax Therapeutics Phase I Trial Results of Antibody Therapy MVT-5873 for the Treatment of Advanced Pancreatic Cancer Presented at the 2017 ASCO Annual Meeting PR Newswire -5.14%
May-25-17 07:05AM  MabVax Therapeutics to Present Phase I Clinical Trial Results of MVT-5873 for the Treatment of Advanced Pancreatic Cancer in Poster Presentation at the 2017 ASCO Annual Meeting PR Newswire
May-24-17 07:05AM  MabVax Therapeutics Reports First Quarter 2017 Operational and Financial Results PR Newswire
May-22-17 07:00AM  MabVax Therapeutics Announces the Closing of its $4.1 Million Public Offering PR Newswire
May-15-17 06:01PM  MabVax Therapeutics Announces $4.1 Million Public Offering PR Newswire
Apr-05-17 08:45AM  MabVax Therapeutics Presents Two Posters at the American Association for Cancer Research (AACR) Annual Meeting on a Novel Radioimmunotherapy Treatment for Pancreatic Cancer PR Newswire
Mar-14-17 02:41PM  MabVax Therapeutics Holdings, Inc. :MBVX-US: Earnings Analysis: 2016 By the Numbers : March 14, 2017 Capital Cube
Feb-24-17 11:00AM  MBVX: Update on Phase 1 Clinical Trials of MVT-5873 and MVT-2163 Zacks Small Cap Research
Feb-23-17 08:30AM  MabVax Therapeutics Announces FDA Authorization to Proceed with MVT-1075 in a Phase I Clinical Trial for the Treatment of Pancreatic Cancer PR Newswire +9.25%
Feb-13-17 08:30AM  MabVax Therapeutics Studies Lead Investigational Drug MVT-5873 with Halozyme PEGPH20 PR Newswire
Feb-10-17 09:00AM  MabVax Therapeutics to Present at the BIO CEO & Investor Conference PR Newswire
Jan-09-17 08:00AM  MabVax Therapeutics Files Investigational New Drug Application for Novel Radioimmunotherapy Agent MVT-1075 PR Newswire
Dec-05-16 08:00AM  MabVax Therapeutics Expands Phase I Clinical Trial Investigation for Patients with Pancreatic Cancer to Include HonorHealth Research Institute PR Newswire +8.42%
Nov-29-16 06:11PM  MabVax Therapeutics Continues to Make Progress in Cancer Detection, Treatment GuruFocus.com
MabVax Therapeutics Holdings, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes proprietary human monoclonal antibody products and vaccines for the treatment of various cancers. The company has a pipeline of human monoclonal antibody products based on the protective immune responses generated by patients who have been immunized against targeted cancers. Its lead cancer vaccines targeting recurrent sarcoma and ovarian cancer are in proof of concept Phase II multi-center clinical trials. The company's product candidates include MVT-5873, a therapeutic antibody that is in Phase I clinical trial for patients with advanced or metastatic adenocarcinoma of the pancreas (PDAC) and other CA19-9 positive malignancies; and MVT-2163, an immuno-positron emission tomography (PET) imaging agent, which is in Phase I clinical trial designed to evaluate a next generation diagnostic PET imaging agent in patients with PDAC or other CA19-9 positive malignancies. Its product candidates also comprise MVT-1075, a radioimmunotherapy agent that combines the company's HuMab-5B1 antibody with the radiopharmaceutical (177) Lutetium to treat pancreatic cancer. The company has various research agreements and collaborations with Memorial Sloan Kettering Cancer Center; a licensing agreement with Life Technologies Corporation; a research collaboration agreement with Rockefeller University's Laboratory of Molecular Genetics and Immunology; and a development and manufacturing services agreement with Patheon. MabVax Therapeutics Holdings, Inc. was founded in 2006 and is based in San Diego, California.